Difference between revisions of "Timeline of diphtheria"
From Timelines
m (Sebastian moved page Timeline of diphteria to Timeline of diphtheria) |
|
(No difference)
| |
Revision as of 06:01, 9 May 2017
| Year/period | Key developments |
|---|
Full timeline
| Year/period | Type of event | Event | Present time geographical location |
|---|---|---|---|
| 5th century BC | Scientific development | Diphtheria is first described by Greek physician Hippocrates.[1] | Greece |
| 1884 | Scientific development | German bacteriologist Friedrich Loeffler first grows diphtheria bacterium corynebacterium diphtheriae in pure culture.[2] | Germany |
| 1921 | Report | 206,000 cases of diphtheria and 15,520 deaths are recorded in the United States.[3] | United States |
| 1974 | Epidemic | Diphtheria epidemic breaks out in Lisbon. 500 persons are involved, and about 40 deaths are recorded.[2] | Portugal |
| 1982 | Epidemic | 5 deaths are recorded in Germany during a diphtheria outbreak.[2] | Germany |
| 1996 | Medical development | Lederle Laboratories licenses diphtheria and tetanus toxoids and acellular pertussis vaccine Acel-Imune, for use as the first through fifth doses in the series.[4] | |
| 1997 | Medical development | British pharmaceutical company SmithKline Beecham licenses Infanrix (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed), for the first four doses of the series.[4] | |
| 1998 | Medical development | North American Vaccine Inc licenses Certiva (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed), for boosting immunization of infants and children.[4] | |
| 1999 | Medical development | Connaught Laboratories licenses diphtheria and tetanus toxoids and acellular pertussis vaccine Tripedia.[4] | |
| 2002 | Medical development | British pharmaceutical GlaxoSmithKline licenses Pediarix, a vaccine combining diphtheria, tetanus, acellular pertussis, inactivated polio, and hepatitis B antigens.[4] | |
| 2002 | Medical development | Aventis Pasteur licenses diphtheria and tetanus toxoids and acellular pertussis vaccine Daptacel.[4] | |
| 2004 | Medical development | Aventis Pasteur licenses vaccine Decavac, indicated for active immunization against tetanus and diphtheria.[4][5] | |
| 2005 | Medical development | Sanofi Pasteur licenses Menactra, the first meningococcal polysaccharide (Serogroups A, C, Y and W-135) diphtheria toxoid conjugate vaccine. This would be the first immunogenic meningococcal vaccine indicated for children younger than 2 years of age.[4] | |
| 2007 | Report | 4,190 cases of diphtheria are reported globally.[3] | |
| 2011 | Medical development | United States Food and Drug Administration approves Boostrix (developed by GlaxoSmithKline) to prevent tetanus, diphtheria, and pertussis in older people.[4] | United States |
See also
- ↑ "Diphtheria". medscape.com. Retrieved 8 May 2017.
- ↑ 2.0 2.1 2.2 KWANTES, W. "Diphtheria in Europe" (PDF). nih.gov. Retrieved 8 May 2017.
- ↑ 3.0 3.1 "Diphtheria: The Plague Among Children". historyofvaccines.org. Retrieved 8 May 2017.
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 "Vaccine Timeline". immunize.org. Retrieved 8 May 2017.
- ↑ "HIGHLIGHTS OF PRESCRIBING INFORMATION" (PDF). vaccineshoppe.com. Retrieved 8 May 2017.
